SEBM 1st European Best Poster Prize awarded at ISCGT Annual Conference in Cork Ireland

October 14, 2009

At this year's Annual Meeting of the International Society for Cell & Gene Therapy of Cancer (ISCGT), held September 2 - 4 in Cork, Ireland, the best poster prize was awarded to an intriguing study in which chicken antibodies were developed for applications in the repair of tissue damage and for potential use in the therapy of cancer metastasis.

The wining abstract, presented to Mr. Tyrone Bowes, a graduate student at REMEDI (Regenerative Medicine Institute) based at the National University of Ireland in Galway states: "We have generated a panel of high affinity scFv antibodies, using chicken immune phage display REMEDI (technology, that bind to the primary cilium of a quiescent population of lineage -ve CD45 +ve Mesenchymal Stem cells (MSC) that reside in human bone marrow. This MSC subset can be readily isolated using Miltenyi MACs system, expanded rapidly in culture and differentiated into bone, cartilage and fat tissue, and are therefore of particular interest in regenerative cell therapy". The group is currently aiming to produce stable functional antibodies for the isolation of MSCs for regenerative cell therapy, and to demonstrate the anti-metastatic potential of humanized antibodies in antibody dependent cellular cytotoxicity (ADCC) assays. This ground breaking study was lead by Professors Timothy O'Brien (Director) and Frank Barry (Scientific Director) of REMEDI.

Presenting the award on behalf of the Society for Experimental Biology and Medicine, Professor Farzin Farzaneh (European Editor of Experimental Biology and Medicine), pointed out the therapeutic potential of the technology developed by the group at REMEDI. The panel of Judges commended Mr. Bowes for his significant contribution, at such an early stage in his research career, to the isolation of high affinity antibodies that are targeted to specific molecules on the surface of tumor and multi-potential adult stem cells.
-end-
The Society for Experimental Biology and Medicine (SEBM) is a not-for-profit scientific society formed to promote investigation in the biomedical sciences by encouraging and facilitating interchange of scientific information among disciplines. To learn about the benefits of society membership visit www.sebm.org. If you are interested in publishing in the journal please visit www.ebmonline.org.

Society for Experimental Biology and Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.